A clinical trial of glutathione supplementation in autism spectrum disorders.

Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR

Medical science monitor : international medical journal of experimental and clinical research1 Dec 2011Cited by 46 (Europe PMC)

PMID22129897PMCIDPMC3628138DOI10.12659/msm.882125PepBankPUB-22129897

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialMechanism
In children with autism spectrum disorders, oral glutathione increased plasma reduced glutathione from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, oral glutathione increased plasma reduced glutathione from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma reduced glutathione after oral treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · oral · eight weeksAs given in this study (human).
Source sentences
Summary
The oral treatment group showed significant increases in plasma reduced glutathione, but not whole-blood glutathione levels following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989701
02HumanNon-randomized trialMechanism
In children with autism spectrum disorders, oral glutathione did not significantly increase whole-blood glutathione from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, oral glutathione did not significantly increase whole-blood glutathione from pretreatment levels.
Peptide
Glutathione
Outcome
No significant changeWhole-blood glutathione after oral treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · oral · eight weeksAs given in this study (human).
Source sentences
Summary
The oral treatment group showed significant increases in plasma reduced glutathione, but not whole-blood glutathione levels following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989702
03HumanNon-randomized trialMechanism
In children with autism spectrum disorders, oral glutathione increased plasma sulfate from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, oral glutathione increased plasma sulfate from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma sulfate after oral treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · oral · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989703
04HumanNon-randomized trialMechanism
In children with autism spectrum disorders, transdermal glutathione increased plasma sulfate from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, transdermal glutathione increased plasma sulfate from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma sulfate after transdermal treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · transdermal · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989704
05HumanNon-randomized trialMechanism
In children with autism spectrum disorders, oral glutathione increased plasma cysteine from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, oral glutathione increased plasma cysteine from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma cysteine after oral treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · oral · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989705
06HumanNon-randomized trialMechanism
In children with autism spectrum disorders, transdermal glutathione increased plasma cysteine from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, transdermal glutathione increased plasma cysteine from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma cysteine after transdermal treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · transdermal · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989706
07HumanNon-randomized trialMechanism
In children with autism spectrum disorders, oral glutathione increased plasma taurine from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, oral glutathione increased plasma taurine from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma taurine after oral treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · oral · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989707
08HumanNon-randomized trialMechanism
In children with autism spectrum disorders, transdermal glutathione increased plasma taurine from pretreatment levels.
In plain wordsIn children with autism spectrum disorders, transdermal glutathione increased plasma taurine from pretreatment levels.
Peptide
Glutathione
Outcome
IncreasePlasma taurine after transdermal treatment
Study
n = 13
Outcome group
Metabolic pathways and metabolomics · Whole body
Studied dose
Dose not stated · transdermal · eight weeksAs given in this study (human).
Source sentences
Summary
Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
Report a problemFND-2212989708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.